Literature DB >> 8441848

Conventional and nonconventional uses of growth hormone.

B M Lippe1, J M Nakamoto.   

Abstract

Although GH has been available as a therapeutic agent for the GH-deficient child for more than 30 years, the conditions of its use have yet to be optimized. The availability of biosynthetic material has provided researchers with the opportunity to develop the protocols necessary to begin to finally answer the most fundamental questions pertaining to dose, frequency, and duration of treatment. It has also permitted the initiation of prospective trials in a large number of conditions that result in childhood short stature, with the expectation that some or many of them will be treated effectively and safely. Finally, it has opened the door to an entire spectrum of potentially new uses of GH and other growth factors for so-called nonconventional indications. That these have implications that range from the short-term rapid healing of a burn graft site, to the more efficient induction of ovulation, to the long-term preservation of lean body mass has excited the interest of investigators in many fields of medicine and physiology. Thus, the recent progress reported in this paper is really the beginning of the new research that will take place with GH and growth factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441848     DOI: 10.1016/b978-0-12-571148-7.50011-7

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  3 in total

Review 1.  Growth hormone cotreatment with gonadotropins in ovulation induction.

Authors:  P G Artini; A A de Micheroux; G D'Ambrogio
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

2.  Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Authors:  J V Gobburu; H Agersø; W J Jusko; L Ynddal
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

3.  Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.

Authors:  T Romer; F Peter; P Saenger; J Starzyk; B Koehler; E Korman; M Walczak; R Wasik; M Ginalska-Malinowska; E Solyom; A Berghout
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.